{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:47:56Z","timestamp":1782485276105,"version":"3.54.5"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00120-026-02840-5","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:58:26Z","timestamp":1778173106000},"page":"719-725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Der Anfang der \u00dcbertherapie\u00a0\u2013 Wie stelle ich die Indikation zur Prostatabiopsie richtig?","Reducing overdiagnosis\u2014how to do I\u00a0correctly assess the indication for prostate biopsy?"],"prefix":"10.1007","volume":"65","author":[{"given":"Felix","family":"Seelemeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouvier","family":"Al-Monajjed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muammar","family":"Dib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jale","family":"Lakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Busshoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Analena","family":"Handke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Boschheidgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Antoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Philipp","family":"Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Schimm\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"2840_CR1","unstructured":"Urology EAo (2025) EAU Guidelines on Prostate Cancer. Arnhem, The Netherlands"},{"key":"2840_CR2","volume-title":"Krebs in Deutschland f\u00fcr 2021\u20132023","author":"e.\u202fV. RK-IGdeKiD","year":"2025","unstructured":"e.\u202fV. RK-IGdeKiD (2025) Krebs in Deutschland f\u00fcr 2021\u20132023. Robert Koch-Institut, Berlin"},{"key":"2840_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/JU.0000000000002696","volume":"208","author":"M Fr\u00e5nlund","year":"2022","unstructured":"Fr\u00e5nlund\u00a0M, M\u00e5nsson\u00a0M, Godtman\u00a0RA et\u00a0al (2022) Results from 22 years of followup in the G\u00f6teborg randomized population-based prostate cancer screening trial. J\u00a0Urol 208:292\u2013300","journal-title":"J Urol"},{"issue":"2","key":"2840_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet\u00a0N, van den Bergh\u00a0RCN, Briers\u00a0E et\u00a0al (2021) EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 79(2):243\u2013262","journal-title":"Eur Urol"},{"key":"2840_CR5","doi-asserted-by":"crossref","unstructured":"de Vos\u00a0II, Marenghi\u00a0C, Badenchini\u00a0F et\u00a0al (2025) Long-term outcomes of active surveillance for Grade Group\u00a01 prostate cancer and the impact of the use of MRI on overtreatment. BJU Int 136(2):245\u2013253","DOI":"10.1111\/bju.16727"},{"key":"2840_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy\u00a0FC, Donovan\u00a0JL, Lane\u00a0JA et\u00a0al (2023) Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N\u00a0Engl J Med 388:1547\u20131558","journal-title":"N Engl J Med"},{"key":"2840_CR7","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1056\/NEJMoa2503223","volume":"393","author":"MJ Roobol","year":"2025","unstructured":"Roobol\u00a0MJ, de V\u00a0VII, M\u00e5nsson\u00a0M et\u00a0al (2025) European study of prostate cancer screening: 23-year follow-up. N\u00a0Engl J Med 393:1669\u20131680","journal-title":"N Engl J Med"},{"key":"2840_CR8","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James\u00a0ND, Tannock\u00a0I, N\u2019Dow\u00a0J et\u00a0al (2024) The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet 403:1683\u20131722","journal-title":"Lancet"},{"key":"2840_CR9","unstructured":"Onkologie L, (AWMF) AdWMF, (DKG) DK, Krebshilfe SD (2025) S3-Leitlinie Prostatakarzinom \u2013 Langversion 8.1. Leitlinienprogramm Onkologie."},{"key":"2840_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071082","volume":"381","author":"A Vickers","year":"2023","unstructured":"Vickers\u00a0A, O\u2019Brien\u00a0F, Montorsi\u00a0F, Galvin\u00a0D, Bratt\u00a0O, Carlsson\u00a0S et\u00a0al (2023) Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit. Bmj 381:e071082","journal-title":"Bmj"},{"issue":"6","key":"2840_CR11","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.eururo.2013.05.022","volume":"64","author":"C Arsov","year":"2013","unstructured":"Arsov\u00a0C, Becker\u00a0N, Hadaschik\u00a0BA et\u00a0al (2013) Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial. Eur Urol 64(6):873\u2013875","journal-title":"Eur Urol"},{"issue":"11","key":"2840_CR12","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/ijc.33940","volume":"150","author":"C Arsov","year":"2022","unstructured":"Arsov\u00a0C, Albers\u00a0P, Herkommer\u00a0K et\u00a0al (2022) A randomized trial of risk-adapted screening for prostate cancer in young men-Results of the first screening round of the PROBASE trial. Int J Cancer 150(11):1861\u20131869","journal-title":"Int J Cancer"},{"key":"2840_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.euros.2024.09.003","volume":"70","author":"A Chandran","year":"2024","unstructured":"Chandran\u00a0A, van Harten\u00a0M, Singh\u00a0D et\u00a0al (2024) Risk-stratified Approach to Implementing Population-based Prostate Cancer Screening in Five Pilot Sites in the European Union: A Protocol for the PRAISE\u2011U Project. Eur Urol Open Sci 70:8\u201317","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"2840_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.eururo.2024.04.030","volume":"86","author":"A Krilaviciute","year":"2024","unstructured":"Krilaviciute\u00a0A, Kaaks\u00a0R, Seibold\u00a0P et\u00a0al (2024) Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial. Eur Urol 86(6):493\u2013500","journal-title":"Eur Urol"},{"issue":"3","key":"2840_CR15","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.eururo.2025.05.020","volume":"88","author":"R Al-Monajjed","year":"2025","unstructured":"Al-Monajjed\u00a0R, Boschheidgen\u00a0M, Lakes\u00a0J et\u00a0al (2025) Prostate Cancer Detection in Younger Men: A Comparative Analysis of Systematic and Magnetic Resonance Imaging\u2013targeted Biopsy in the PROBASE Trial. European Urology 88(3):240\u2013244","journal-title":"European Urology"},{"issue":"1","key":"2840_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/21681805.2017.1411392","volume":"52","author":"J Hugosson","year":"2018","unstructured":"Hugosson\u00a0J, Godtman\u00a0RA, Carlsson\u00a0SV et\u00a0al (2018) Eighteen-year follow-up of the G\u00f6teborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand J Urol 52(1):27\u201337","journal-title":"Scand J Urol"},{"issue":"16","key":"2840_CR17","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1200\/JCO.19.02808","volume":"38","author":"JL Beebe-Dimmer","year":"2020","unstructured":"Beebe-Dimmer\u00a0JL, Kapron\u00a0AL, Fraser\u00a0AM et\u00a0al (2020) Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes. J\u00a0Clin Oncol 38(16):1807\u20131813","journal-title":"J Clin Oncol"},{"issue":"11","key":"2840_CR18","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/S1470-2045(21)00522-2","volume":"22","author":"EK Bancroft","year":"2021","unstructured":"Bancroft\u00a0EK, Page\u00a0EC, Brook\u00a0MN et\u00a0al (2021) A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncol 22(11):1618\u20131631","journal-title":"Lancet Oncol"},{"issue":"6","key":"2840_CR19","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.euo.2023.09.008","volume":"6","author":"A Krilaviciute","year":"2023","unstructured":"Krilaviciute\u00a0A, Becker\u00a0N, Lakes\u00a0J et\u00a0al (2023) Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer. Eur Urol Oncol 6(6):566\u2013573","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"2840_CR20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.euo.2023.12.005","volume":"7","author":"A Matsukawa","year":"2024","unstructured":"Matsukawa\u00a0A, Yanagisawa\u00a0T, Bekku\u00a0K et\u00a0al (2024) Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol 7(4):697\u2013704","journal-title":"Eur Urol Oncol"},{"issue":"10071","key":"2840_CR21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed\u00a0HU, El-Shater Bosaily\u00a0A, Brown\u00a0LC et\u00a0al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet 389(10071):815\u2013822","journal-title":"The Lancet"},{"issue":"19","key":"2840_CR22","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan\u00a0V, Rannikko\u00a0AS, Borghi\u00a0M et\u00a0al (2018) MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. New England Journal of Medicine 378(19):1767\u20131777","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"2840_CR23","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"M van der Leest","year":"2019","unstructured":"van der Leest\u00a0M, Cornel\u00a0E, Isra\u00ebl\u00a0B et\u00a0al (2019) Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-na\u00efve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. European Urology 75(4):570\u2013578","journal-title":"European Urology"},{"issue":"2","key":"2840_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1001\/jamaoncol.2024.5497","volume":"11","author":"CA Hamm","year":"2025","unstructured":"Hamm\u00a0CA, Asbach\u00a0P, P\u00f6hlmann\u00a0A et\u00a0al (2025) Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer. JAMA Oncology 11(2):145\u2013153","journal-title":"JAMA Oncology"},{"issue":"1","key":"2840_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","volume":"20","author":"O Rouvi\u00e8re","year":"2019","unstructured":"Rouvi\u00e8re\u00a0O, Puech\u00a0P, Renard-Penna\u00a0R, Claudon\u00a0M, Roy\u00a0C, M\u00e8ge-Lechevallier\u00a0F et\u00a0al (2019) Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol 20(1):100\u2013109","journal-title":"Lancet Oncol"},{"issue":"9","key":"2840_CR26","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamasurg.2019.1734","volume":"154","author":"FF Elkhoury","year":"2019","unstructured":"Elkhoury\u00a0FF, Felker\u00a0ER, Kwan\u00a0L et\u00a0al (2019) Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study. JAMA Surg 154(9):811\u2013818","journal-title":"JAMA Surg"},{"issue":"2","key":"2840_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.euo.2020.02.005","volume":"3","author":"A Stabile","year":"2020","unstructured":"Stabile\u00a0A, Giganti\u00a0F, Kasivisvanathan\u00a0V et\u00a0al (2020) Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review. Eur Urol Oncol 3(2):145\u2013167","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"2840_CR28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey\u00a0B, Rosenkrantz\u00a0AB, Haider\u00a0MA et\u00a0al (2019) Prostate Imaging Reporting and Data System Version\u00a02.1: 2019 Update of Prostate Imaging Reporting and Data System Version\u00a02. Eur Urol 76(3):340\u2013351","journal-title":"Eur Urol"},{"key":"2840_CR29","doi-asserted-by":"crossref","unstructured":"Thorley N, Parry T, Giganti F, et\u00a0al. (2025) Diagnostic accuracy of abbreviated biparametric MRI for prostate cancer screening: a\u00a0prospective feasibility study (ReIMAGINE study). Eur Radiol","DOI":"10.1007\/s00330-025-11837-1"},{"issue":"13","key":"2840_CR30","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jama.2025.13722","volume":"334","author":"ABCD Ng","year":"2025","unstructured":"Ng\u00a0ABCD, Asif\u00a0A, Agarwal\u00a0R et\u00a0al (2025) Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial. JAMA 334(13):1170\u20131179","journal-title":"JAMA"},{"key":"2840_CR31","doi-asserted-by":"crossref","unstructured":"Nedelcu A, Oerther B, Benkendorff A, et\u00a0al. (2025) PI-RADS Version\u00a02.1 for Prostate MRI Interpretation: Associations of Study Quality and Cancer Detection Metrics\u2011A Systematic Review and Meta-Analysis. AJR Am J Roentgenol","DOI":"10.2214\/AJR.25.33583"},{"issue":"1","key":"2840_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/jmri.27180","volume":"53","author":"AR Padhani","year":"2021","unstructured":"Padhani\u00a0AR, Schoots\u00a0I, Villeirs\u00a0G (2021) Contrast Medium or No Contrast Medium for Prostate Cancer Diagnosis. That Is the Question. Journal of Magnetic Resonance Imaging 53(1):13\u201322","journal-title":"Journal of Magnetic Resonance Imaging"},{"issue":"5","key":"2840_CR33","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/S0022-5347(05)00957-2","volume":"175","author":"K Eichler","year":"2006","unstructured":"Eichler\u00a0K, Hempel\u00a0S, Wilby\u00a0J et\u00a0al (2006) Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a\u00a0systematic review. J\u00a0Urol 175(5):1605\u20131612","journal-title":"J Urol"},{"issue":"23","key":"2840_CR34","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","volume":"387","author":"J Hugosson","year":"2022","unstructured":"Hugosson\u00a0J, M\u00e5nsson\u00a0M, Wallstr\u00f6m\u00a0J et\u00a0al (2022) Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N\u00a0Engl J Med 387(23):2126\u20132137","journal-title":"N Engl J Med"},{"issue":"10","key":"2840_CR35","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/NEJMoa2100852","volume":"385","author":"M Eklund","year":"2021","unstructured":"Eklund\u00a0M, J\u00e4derling\u00a0F, Discacciati\u00a0A et\u00a0al (2021) MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. N\u00a0Engl J Med 385(10):908\u2013920","journal-title":"N Engl J Med"},{"issue":"5","key":"2840_CR36","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/ijc.34295","volume":"152","author":"A Krilaviciute","year":"2023","unstructured":"Krilaviciute\u00a0A, Albers\u00a0P, Lakes\u00a0J et\u00a0al (2023) Adherence to a risk-adapted screening strategy for prostate cancer: First results of the PROBASE trial. Int J Cancer 152(5):854\u2013864","journal-title":"Int J Cancer"},{"issue":"2","key":"2840_CR37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.prnil.2023.01.003","volume":"11","author":"S Cetin","year":"2023","unstructured":"Cetin\u00a0S, Huseyinli\u00a0A, Koparal\u00a0MY et\u00a0al (2023) How many cores should be taken from each region of interest when performing a targeted transrectal prostate biopsy? Prostate Int 11(2):122\u2013126","journal-title":"Prostate Int"},{"issue":"3","key":"2840_CR38","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41391-022-00599-2","volume":"26","author":"NL Beetz","year":"2023","unstructured":"Beetz\u00a0NL, Dr\u00e4ger\u00a0F, Hamm\u00a0CA et\u00a0al (2023) MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed. Prostate Cancer Prostatic Dis 26(3):543\u2013551","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"2840_CR39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.prnil.2020.03.004","volume":"8","author":"G Sonmez","year":"2020","unstructured":"Sonmez\u00a0G, Demirtas\u00a0T, Tombul\u00a0ST et\u00a0al (2020) What is the ideal number of biopsy cores per lesion in targeted prostate biopsy? Prostate Int 8(3):112\u2013115","journal-title":"Prostate Int"},{"key":"2840_CR40","doi-asserted-by":"crossref","unstructured":"Lombardo R, Tema G, Nacchia A, et\u00a0al. (2023) Role of Perilesional Sampling of Patients Undergoing Fusion Prostate Biopsies. Life (Basel);13(8)","DOI":"10.3390\/life13081719"},{"issue":"5","key":"2840_CR41","doi-asserted-by":"publisher","first-page":"192.e11","DOI":"10.1016\/j.urolonc.2022.01.011","volume":"40","author":"R Diamand","year":"2022","unstructured":"Diamand\u00a0R, Hollans\u00a0M, Lefebvre\u00a0Y et\u00a0al (2022) The role of perilesional and multiparametric resonance imaging-targeted biopsies to reduce the risk of upgrading at radical prostatectomy pathology: A retrospective monocentric study. Urologic Oncology: Seminars and Original Investigations 40(5):192.e11\u2013192.e17","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"issue":"1","key":"2840_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.euo.2022.08.005","volume":"6","author":"YM Saner","year":"2023","unstructured":"Saner\u00a0YM, Wiesenfarth\u00a0M, Weru\u00a0V et\u00a0al (2023) Detection of Clinically Significant Prostate Cancer Using Targeted Biopsy with Four Cores Versus Target Saturation Biopsy with Nine Cores in Transperineal Prostate Fusion Biopsy: A Prospective Randomized Trial. European Urology Oncology 6(1):49\u201355","journal-title":"European Urology Oncology"},{"issue":"6","key":"2840_CR43","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.euf.2020.06.020","volume":"7","author":"S Tschirdewahn","year":"2021","unstructured":"Tschirdewahn\u00a0S, Wiesenfarth\u00a0M, Bonekamp\u00a0D et\u00a0al (2021) Detection of Significant Prostate Cancer Using Target Saturation in Transperineal Magnetic Resonance Imaging\/Transrectal Ultrasonography\u2013fusion Biopsy. European Urology Focus 7(6):1300\u20131307","journal-title":"European Urology Focus"},{"issue":"3","key":"2840_CR44","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41391-022-00620-8","volume":"26","author":"JP Noujeim","year":"2023","unstructured":"Noujeim\u00a0JP, Belahsen\u00a0Y, Lefebvre\u00a0Y et\u00a0al (2023) Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling. Prostate Cancer Prostatic Dis 26(3):575\u2013580","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"2840_CR45","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.eururo.2015.06.008","volume":"68","author":"C Arsov","year":"2015","unstructured":"Arsov\u00a0C, Rabenalt\u00a0R, Blondin\u00a0D et\u00a0al (2015) Prospective Randomized Trial Comparing Magnetic Resonance Imaging (MRI)-guided In-bore Biopsy to MRI-ultrasound Fusion and Transrectal Ultrasound-guided Prostate Biopsy in Patients with Prior Negative Biopsies. European Urology 68(4):713\u2013720","journal-title":"European Urology"},{"key":"2840_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2024.111436","volume":"175","author":"M Quentin","year":"2024","unstructured":"Quentin\u00a0M, Boschheidgen\u00a0M, Radtke\u00a0JP et\u00a0al (2024) MRI in-bore biopsy following MRI\/US fusion-guided biopsy in patients with persistent suspicion of clinically significant prostate cancer. European Journal of Radiology 175:111436","journal-title":"European Journal of Radiology"},{"issue":"1","key":"2840_CR47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.eururo.2023.12.015","volume":"86","author":"JC Hu","year":"2024","unstructured":"Hu\u00a0JC, Assel\u00a0M, Allaf\u00a0ME et\u00a0al (2024) Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol 86(1):61\u201368","journal-title":"Eur Urol"},{"issue":"1","key":"2840_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/JU.0000000000003979","volume":"212","author":"BM Mian","year":"2024","unstructured":"Mian\u00a0BM, Feustel\u00a0PJ, Aziz\u00a0A et\u00a0al (2024) Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the Prostate Biopsy Efficacy and Complications Randomized Clinical Trial. J\u00a0Urol 212(1):21\u201331","journal-title":"J Urol"},{"issue":"5","key":"2840_CR49","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.euo.2024.01.019","volume":"7","author":"G Ploussard","year":"2024","unstructured":"Ploussard\u00a0G, Barret\u00a0E, Fiard\u00a0G et\u00a0al (2024) Transperineal Versus Transrectal Magnetic Resonance Imaging\u2013targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1). European Urology Oncology 7(5):1080\u20131087","journal-title":"European Urology Oncology"},{"issue":"5","key":"2840_CR50","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1470-2045(25)00100-7","volume":"26","author":"RJ Bryant","year":"2025","unstructured":"Bryant\u00a0RJ, Marian\u00a0IR, Williams\u00a0R et\u00a0al (2025) Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial. Lancet Oncol 26(5):583\u2013595","journal-title":"Lancet Oncol"},{"issue":"19","key":"2840_CR51","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2025.3579","volume":"333","author":"A Kinnaird","year":"2025","unstructured":"Kinnaird\u00a0A, Luger\u00a0F, Cash\u00a0H et\u00a0al (2025) Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial. JAMA 333(19):1679\u20131687","journal-title":"JAMA"},{"key":"2840_CR52","doi-asserted-by":"crossref","unstructured":"Krausewitz P, Essler M, Gaertner FC, et\u00a0al. (2025) Impact of Initial Prostate-Specific Membrane Antigen PET\/CT Staging and Prostate-Specific Membrane Antigen\u2013Targeted Biopsy on Treatment Decisions in Prostate Cancer: Results from the Phase\u00a02 DEPROMP Trial. Journal of Nuclear Medicine. jnumed.125.271344","DOI":"10.2967\/jnumed.125.271344"},{"issue":"4","key":"2840_CR53","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2967\/jnumed.123.266742","volume":"65","author":"J Shi","year":"2024","unstructured":"Shi\u00a0J, Li\u00a0D, Chen\u00a0M et\u00a0al (2024) The Value of (68)Ga-PSMA PET\/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study. J\u00a0Nucl Med 65(4):555\u2013559","journal-title":"J Nucl Med"},{"issue":"5","key":"2840_CR54","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.euo.2020.12.004","volume":"4","author":"E Mazzone","year":"2021","unstructured":"Mazzone\u00a0E, Stabile\u00a0A, Pellegrino\u00a0F et\u00a0al (2021) Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol 4(5):697\u2013713","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"2840_CR55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/JU.0000000000000757","volume":"204","author":"MA Pagniez","year":"2020","unstructured":"Pagniez\u00a0MA, Kasivisvanathan\u00a0V, Puech\u00a0P et\u00a0al (2020) Predictive Factors of Missed Clinically Significant Prostate Cancers in Men with Negative Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis. J\u00a0Urol 204(1):24\u201332","journal-title":"J Urol"},{"issue":"2","key":"2840_CR56","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/bju.15277","volume":"127","author":"IG Schoots","year":"2021","unstructured":"Schoots\u00a0IG, Padhani\u00a0AR (2021) Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation. BJU Int 127(2):175\u2013178","journal-title":"BJU Int"},{"issue":"16","key":"2840_CR57","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1002\/pros.24078","volume":"80","author":"N Omri","year":"2020","unstructured":"Omri\u00a0N, Kamil\u00a0M, Alexander\u00a0K et\u00a0al (2020) Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume. Prostate 80(16):1444\u20131449","journal-title":"Prostate"},{"issue":"1","key":"2840_CR58","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00345-022-04185-y","volume":"41","author":"MJ Hagens","year":"2023","unstructured":"Hagens\u00a0MJ, Stelwagen\u00a0PJ, Veerman\u00a0H et\u00a0al (2023) External validation of the Rotterdam prostate cancer risk calculator within a high-risk Dutch clinical cohort. World J Urol 41(1):13\u201318","journal-title":"World J Urol"},{"issue":"2","key":"2840_CR59","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.euo.2018.02.010","volume":"1","author":"CK Mannaerts","year":"2018","unstructured":"Mannaerts\u00a0CK, Gayet\u00a0M, Verbeek\u00a0JF et\u00a0al (2018) Prostate Cancer Risk Assessment in Biopsy-na\u00efve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy. Eur Urol Oncol 1(2):109\u2013117","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"2840_CR60","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.eururo.2024.04.037","volume":"86","author":"A Josefsson","year":"2024","unstructured":"Josefsson\u00a0A, M\u00e5nsson\u00a0M, Kohestani\u00a0K et\u00a0al (2024) Performance of 4Kscore as a\u00a0Reflex Test to Prostate-specific Antigen in the G\u00d6TEBORG\u20112 Prostate Cancer Screening Trial. European Urology 86(3):223\u2013229","journal-title":"European Urology"},{"issue":"17","key":"2840_CR61","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1001\/jama.2024.3841","volume":"331","author":"A Auvinen","year":"2024","unstructured":"Auvinen\u00a0A, Tammela\u00a0TLJ, Mirtti\u00a0T et\u00a0al (2024) Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial. Jama 331(17):1452\u20131459","journal-title":"Jama"},{"issue":"5","key":"2840_CR62","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/JU.0000000000004437","volume":"213","author":"A Lazarovich","year":"2025","unstructured":"Lazarovich\u00a0A, Vigneswaran\u00a0H, Palsdottir\u00a0T et\u00a0al (2025) A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial. J\u00a0Urol 213(5):590\u2013599","journal-title":"J Urol"},{"issue":"14","key":"2840_CR63","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa2407934","volume":"392","author":"JK McHugh","year":"2025","unstructured":"McHugh\u00a0JK, Bancroft\u00a0EK, Saunders\u00a0E et\u00a0al (2025) Assessment of a Polygenic Risk Score in Screening for Prostate Cancer. N\u00a0Engl J Med 392(14):1406\u20131417","journal-title":"N Engl J Med"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02840-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02840-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02840-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:04:59Z","timestamp":1782482699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02840-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2840"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02840-5","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Seelemeyer, R.\u00a0Al-Monajjed, M.\u00a0Dib, J.\u00a0Lakes, I.\u00a0Busshoff, A.\u00a0Handke, M.\u00a0Boschheidgen, G.\u00a0Antoch, P.\u00a0Albers, J.P.\u00a0Radtke und L.\u00a0Schimm\u00f6ller geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}